(MENAFN) US pharmaceutical titan Pfizer posted a slight increase of earnings in the third-quarter period on stronger sales in vaccines and some other products, AFP reported.
The pharmaceutical giant's earnings for the July-September period came in at USD2.7 billion, up 2.9 percent from the year-ago period on slightly lower total sales.
Revenues in some segments fell due to generic competition for several leading drugs, including the sexual dysfunction medication Viagra and the incontinence drug Detrol.
However, Pfizer posted a 19 percent rise in global vaccines revenues, led in part by the surge in use of Prevnar, whose uses include prevention of pneumonia in seniors.
"I am pleased with our third-quarter financial results despite the continued negative impact from product losses of exclusivity and the termination of certain co-promotion collaborations," chief financial officer said.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.